期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 10, 期 12, 页码 1811-1825出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.73
关键词
biomarkers; genomic; motor; neurochemical; neuroimaging; non-motor; Parkinson's disease
资金
- Singapore General Hospital
- National Neuroscience Institute
- Duke-NUS Graduate Medical School, Singapore
- Millennium Foundation
- National Medical Research Council
Parkinson's disease (PD) is the most common neurodegenerative movement disorder, affecting over 6 million people worldwide. It is anticipated that the number of affected individuals may increase significantly in the most populous nations by 2030. During the past 20 years, much progress has been made in identifying and assessing various potential clinical, biochemical, imaging and genetic biomarkers for PD. Despite the wealth of information, development of a validated biomarker for PD is still ongoing. It is hoped that reliable and well-validated biomarkers will provide critical clues to assist in the diagnosis and management of Parkinson's disease patients in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据